-
Cancer company Aravive's US stock market plummeted by over 57% before trading
On January 18th, the US stock market of cancer company Aravive plummeted by over 57% to $0.046. Previously, the company announced that it would voluntarily delist from the Nasdaq Global Select Market ... -
AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
On December 26th, AstraZeneca announced that it had signed a final agreement on its acquisition proposal for Genxi Biotechnology. This proposed acquisition will add GC012F CAR-T cell therapy to Astra ... -
Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the ...